Cargando…
Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy
FR901464 (FR) was first described as an anticancer drug and later identified as a modulator of splicing factor 3B subunit 1 (SF3B1). Although the effectiveness of splicing modulators has been investigated in colorectal cancer (CRC) cells, their usefulness in animal experiments has not been confirmed...
Autores principales: | Yamano, Tomoki, Kubo, Shuji, Yano, Aya, Kominato, Tomoko, Tanaka, Shino, Ikeda, Masataka, Tomita, Naohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349454/ https://www.ncbi.nlm.nih.gov/pubmed/30719229 http://dx.doi.org/10.18632/oncotarget.26564 |
Ejemplares similares
-
Synthesis and
Conformational Analysis of FR901464-Based
RNA Splicing Modulators and Their Synergism in Drug-Resistant Cancers
por: Beard, Jacob P., et al.
Publicado: (2023) -
Enantioselective Total Syntheses
of FR901464 and Spliceostatin
A and Evaluation of Splicing Activity of Key Derivatives
por: Ghosh, Arun K., et al.
Publicado: (2014) -
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model
por: Yamano, Tomoki, et al.
Publicado: (2016) -
A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma
por: Yamano, Tomoki, et al.
Publicado: (2020) -
Assessment of circulating microRNA specific for patients with familial adenomatous polyposis
por: Yamano, Tomoki, et al.
Publicado: (2021)